Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Andrea GS Pepper, PhD, Antonella Zucchetto, PhD, Kevin Norris, PhD, Erika Tissino, PhD, Jerry Polesel, Zarni Soe, David Allsup, Anna Hockaday, Pei Loo Ow, Peter Hillmen, MBChB, PhD, Andrew Rawstron, PhD, Daniel Catovsky, MD FRCP, Riccardo Bomben, PhD, Duncan M Baird, PhD, Christopher Fegan, Valter Gattei, MD, Chris Pepper, BSc, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-141279

Published: 2020

Journal Articles

The Association between Deaths Due to Infection and Mutations of the BRAF, FBXW7, NRAS and XPO1 genes: A Report from the LRF CLL4 Trial

Monica Else, MA,MSc, Stuart J Blakemore, PhD, Jonathan C Strefford, PhD, Daniel Catovsky, MD FRCP

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134544

Published: 2020

Journal Articles

The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial

Blood (2017) 130 (Supplement 1): 259.

https://doi.org/10.1182/blood.V130.Suppl_1.259.259

Published: 2017

Journal Articles

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

Blood (2017) 130 (Supplement 1): 56.

https://doi.org/10.1182/blood.V130.Suppl_1.56.56

Published: 2017

Journal Articles

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Anton Parker, Ben Gregory, Zadie Davis, Monica Else, MA, MSc, Matthew JJ Rose-Zerilli, PhD, Jonathan C Strefford, Daniel Catovsky, MD, DSc(Med), David Oscier

Blood (2013) 122 (21): 4137.

https://doi.org/10.1182/blood.V122.21.4137.4137

Published: 2013

Journal Articles

Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas

Veronica Sylvina Gil, PhD, Sven Stengel, PhD, Govind Bhagat, MD, Louise Howell, BSc, Daniel Catovsky, MD, Laura Pasqualucci, MD, Kevin Petrie, PhD, Arthur Zelent, PhD

Blood (2012) 120 (21): 3505.

https://doi.org/10.1182/blood.V120.21.3505.3505

Published: 2012

Journal Articles

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

Ana Marin-Niebla, MD, Monica Else, MA, MSc, Fatima De la Cruz, MD, Paul Batty, MD, Eduardo Rios-Herranz, MD, Claire E. Dearden, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez Simón, MD, PhD, Daniel Catovsky, MD, Estella Matutes

Blood (2011) 118 (21): 4986.

https://doi.org/10.1182/blood.V118.21.4986.4986

Published: 2011

Journal Articles

The Outcome of CLL Patients with 97% Identity to Germline Is Inferior to Other ‘Mutated’ Cases Defined by a 98% Cut off

Zadie Davis, PhD, Anton Parker, Daniel Catovsky, MD, David Oscier, MD

Blood (2011) 118 (21): 2842.

https://doi.org/10.1182/blood.V118.21.2842.2842

Published: 2011

Journal Articles

Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,

Anton Parker, Jade Forster, Stacey Reichter, David Gonzalez de Castro, PhD, Daniel Catovsky, MD, David Oscier, MD

Blood (2011) 118 (21): 3884.

https://doi.org/10.1182/blood.V118.21.3884.3884

Published: 2011

Journal Articles

Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.

Sarah L Hockley, PhD, Alison Morilla, Andrew Wotherspoon, MD, PhD, Brian A Walker, PhD, Nicholas J Dickens, PhD, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD, Estella Matutes, MD, PhD, David Gonzalez, PhD

Blood (2009) 114 (22): 3467.

https://doi.org/10.1182/blood.V114.22.3467.3467

Published: 2009

Journal Articles

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion

David Gonzalez, PhD, Pilar Martinez, MD, PhD, Rachel Wade, Sarah Lorna Hockley, PhD, Vasantha Brito-Babapulle, PhD, David Graham Oscier, MD, Estella Matutes, MD, PhD, Claire E Dearden, Sue Richards, Daniel Catovsky, MD, Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 784.

https://doi.org/10.1182/blood.V112.11.784.784

Published: 2008

Journal Articles

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant

Sarah L Hockley, PhD, Monica Else, MA, MSc, Paola E Leone, PhD, Brian A Walker, Alison Morilla, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD, Estella Matutes, MD, PhD, David Gonzalez, PhD

Blood (2008) 112 (11): 3136.

https://doi.org/10.1182/blood.V112.11.3136.3136

Published: 2008

Journal Articles

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Sarah L Hockley, PhD, David Gonzalez, PhD, Vasantha Brito-Babapulle, PhD, Monica Else, MA, MSc, Paola E Leone, Brian A Walker, Estella Matutes, MD, PhD, Claire E Dearden, MD, Daniel Catovsky, MD, DSc(Med), Gareth J Morgan, MD, PhD

Blood (2008) 112 (11): 3140.

https://doi.org/10.1182/blood.V112.11.3140.3140

Published: 2008

Journal Articles

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Monica Else, MA, MSc, Claire E. Dearden, MD, Estella Matutes, MD, Ama Z S Rohatiner, MD, Steve A N Johnson, MD, Nigel T J O’Connor, MD, Andy Haynes, MD, Nnenna Osuji, MD, Daniel Catovsky, MD, DSc(Med)

Blood (2008) 112 (11): 2101.

https://doi.org/10.1182/blood.V112.11.2101.2101

Published: 2008

Journal Articles

Baseline Characteristics Associated with Quality of Life in CLL Patients Requiring Therapy.

Monica Else, MSc, Alastair G. Smith, MD, Sue M. Richards, DPhil, Kim Cocks, MSc, Shirley Crofts, MSc, Daniel Catovsky, MD

Blood (2007) 110 (11): 2062.

https://doi.org/10.1182/blood.V110.11.2062.2062

Published: 2007

Journal Articles

The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.

Daniel Catovsky, MD, DSc, Monica Else, MA MSc, Sue Richards, D Phil, Peter Hillmen, MD PhD

Blood (2006) 108 (11): 304.

https://doi.org/10.1182/blood.V108.11.304.304

Published: 2006

Journal Articles

Prognostic Factors in the UK LRF CLL4 Trial.

David Graham Oscier, MD, Rachel Wade, MSc, Jenny Orchard, MD, Zadie Davis, MSc, Giles Best, PhD, Alison Morilla, BSc, Vasantha Brito-Bapapulle, PhD, Estella Matutes, MD, Sue Richards, DPhil, Daniel Catovsky, MD

Blood (2006) 108 (11): 299.

https://doi.org/10.1182/blood.V108.11.299.299

Published: 2006

Journal Articles

Drug Sensitivity by TRAC (DiSC) Assay as a Prognostic Factor for Patient Response in Untreated CLL: Results from the UK LRF CLL4 Trial.

Andrew G. Bosanquet, PhD, Steve L. Raper, BSc, Justin Durant, Sheila M. Scadding, David Graham Oscier, MD, Sue M. Richards, PhD, Daniel Catovsky, MD PhD, on Behalf of the NCRI CLL Working Group

Blood (2006) 108 (11): 303.

https://doi.org/10.1182/blood.V108.11.303.303

Published: 2006

Journal Articles

Combined aCGH and Mutational Analysis of CLL Patients with 17p Deletion.

Hannah C. Rudenko, MSc, Vasantha Brito-Babapulle, PhD, David Gonzalez, PhD, Pilar Martinez, MD, Paola E. Leone, PhD, Chris Jones, PhD, Tim Dexter, PhD, Kerry Fenwick, MSc, Alan Mackay, BSc, Alan Ashworth, PhD, Estella Matutes, MD, Daniel Catovsky, MD, Claire Dearden, MD, Gareth J. Morgan, MD,PhD

Blood (2006) 108 (11): 2091.

https://doi.org/10.1182/blood.V108.11.2091.2091

Published: 2006

Journal Articles

Prognostic Factors in the UK LRF CLL4 Trial.

David Graham Oscier, MD, Sue Richards, DPhil, Jenny Orchard, MD, Zadie Davis, MSc, Giles Best, PhD, Alison Morilla, BSc, Vasantha Brito-Bapapulle, PhD, Estella Matutes, MD, Andrew Pettitt, MD, Daniel Catovsky, MD

Blood (2005) 106 (11): 2099.

https://doi.org/10.1182/blood.V106.11.2099.2099

Published: 2005

NARROW

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

The Association between Deaths Due to Infection and Mutations of the BRAF, FBXW7, NRAS and XPO1 genes: A Report from the LRF CLL4 Trial

The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

ZAP70 Methylation Is An Independent Prognostic Biomarker For Front Line Therapy Of Chronic Lymphocytic Leukemia : Results From The UK LRF CLL4 Trial

Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas

Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL)

The Outcome of CLL Patients with 97% Identity to Germline Is Inferior to Other ‘Mutated’ Cases Defined by a 98% Cut off

Telomere Length Is An Independent Predictor of Outcome After Therapy in CLL: Results From the UKCLL4 Trial,

Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.

Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion

High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant

Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study

Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.

Baseline Characteristics Associated with Quality of Life in CLL Patients Requiring Therapy.

The Lack of Survival Differences in Randomised Trials in CLL May Be Related to the Effect of Second Line Therapies. A Report from the LRF CLL4 Trial.

Prognostic Factors in the UK LRF CLL4 Trial.

Drug Sensitivity by TRAC (DiSC) Assay as a Prognostic Factor for Patient Response in Untreated CLL: Results from the UK LRF CLL4 Trial.

Combined aCGH and Mutational Analysis of CLL Patients with 17p Deletion.

Prognostic Factors in the UK LRF CLL4 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only